Conv. Plasma
Nigella Sativa

All tixagevimab/cilgavimab..
Meta analysis
study COVID-19 treatment researchTixagevimab/cilgavimabTixagev../c.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

COVID-19 morbidity decreases with tixagevimab–cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders

Kaminski et al., Kidney International, doi:10.1016/j.kint.2022.07.008
Oct 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 92% Improvement Relative Risk ICU admission 96% Hospitalization 95% Symp. case 99% Tixagevimab/c..  Kaminski et al.  Prophylaxis Is prophylaxis with tixagevimab/cilgavimab beneficial for COVID-19? Retrospective 430 patients in France (December 2021 - February 2022) Lower ICU admission (p=0.001) and hospitalization (p=0.001) Kaminski et al., Kidney Int., October 2022 Favorstixagevimab/ci.. Favorscontrol 0 0.5 1 1.5 2+
39th treatment shown to reduce risk in May 2022
*, now with p = 0.000029 from 17 studies, recognized in 31 countries. Efficacy is variant dependent.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments.
Retrospective 430 kidney transplant recipients showing significantly lower symptomatic COVID-19 and hospitalization with tixagevimab/cilgavimab preexposure prophylaxis compared to 97 patients who did not receive it, during an omicron wave.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2.75.2, BA.4.6, BQ.1.11, BA.5, BA.2.75, XBB2, ХВВ.1.9.1, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.13.
risk of death, 92.4% lower, HR 0.08, p = 0.07, treatment 1 of 333 (0.3%), control 2 of 97 (2.1%), NNT 57, Cox proportional hazards.
risk of ICU admission, 95.5% lower, HR 0.04, p = 0.001, treatment 2 of 333 (0.6%), control 6 of 97 (6.2%), NNT 18, Cox proportional hazards.
risk of hospitalization, 95.4% lower, HR 0.05, p = 0.001, treatment 4 of 333 (1.2%), control 11 of 97 (11.3%), NNT 9.9, Cox proportional hazards.
risk of symptomatic case, 98.9% lower, HR 0.01, p = 0.001, treatment 41 of 333 (12.3%), control 42 of 97 (43.3%), NNT 3.2, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kaminski et al., 31 Oct 2022, retrospective, France, peer-reviewed, 21 authors, study period 28 December, 2021 - 28 February, 2022. Contact:
This PaperTixagev../c..All
Abstract: Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. letters to the editor COVID-19 morbidity decreases with tixagevimab–cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders To the editor: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with high mortality in kidney transplant recipients (KTRs).1 Unfortunately, they display a poor humoral immune response following coronavirus disease 2019 (COVID-19) mRNA vaccination.2 The use of anti–SARS-CoV-2 monoclonal antibodies was therefore proposed for preexposure prophylaxis in individuals who did not exhibit a significant antibody response following vaccination. Tixagevimab–cilgavimab (Evusheld; AstraZeneca) was found to be effective in preventing COVID19 during Alpha and Delta waves.3 Because it retained a neutralizing activity against the Omicron variants BA.1 and BA.2, it was approved in many countries for preexposure prophylaxis of KTRs with a low anti–SARS-CoV-2 antibody response after vaccination.4,5 A recent study of Bertrand et al. revealed the potential clinical efficiency of tixagevimab– cilgavimab against Omicron in KTRs with weak or no response to vaccine.6 At the same time, Benotmane et al. reported serious Omicron infections despite prophylactic therapy using tixagevimab–cilgavimab.7 In light of these conflicting data, we report herein the impact of this preexposure prophylaxis on the incidence of symptomatic COVID-19; COVID-19–related hospitalizations, including intensive care unit hospitalizations; and death in a cohort of KTRs during the Omicron wave. KTRs from Bordeaux University Hospital (France) were considered as nonresponders or low responders if they had an anti-spike antibody level of <7 binding antibody units/ml (threshold of detection) or between 7 and 264 binding antibody units/ml, respectively, after at least 3 doses of mRNA vaccines. All patients were to receive i.m. prophylactic injections of tixagevimab–cilgavimab (150 mg tixagevimab and 150 mg cilgavimab) between December 28, 2021, and February 28, 2022 (COVID-19 incidence of 779 of 100,000). This period corresponded to the peak of the Omicron wave observed on January 27, 2022 (COVID-19 incidence of 4021 of 100,000) in our region ( During this study period, BA.1 was the predominant variant until February 14, 2022, when the BA.2 variant became predominant. The last follow-up was on May 5, 2022. Diagnosis of COVID-19 was based on the reverse transcriptase–polymerase chain reaction of nasopharyngeal swabs, and genome sequencing was 936 performed when suitable samples were available. All the data were recovered from our database (Réseau Aquitain..
{ 'indexed': {'date-parts': [[2024, 1, 6]], 'date-time': '2024-01-06T22:59:56Z', 'timestamp': 1704581996063}, 'reference-count': 7, 'publisher': 'Elsevier BV', 'issue': '4', 'license': [ { 'start': { 'date-parts': [[2022, 10, 1]], 'date-time': '2022-10-01T00:00:00Z', 'timestamp': 1664582400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': ''}], 'content-domain': { 'domain': ['', '', ''], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2022, 10]]}, 'DOI': '10.1016/j.kint.2022.07.008', 'type': 'journal-article', 'created': {'date-parts': [[2022, 7, 20]], 'date-time': '2022-07-20T15:31:56Z', 'timestamp': 1658331116000}, 'page': '936-938', 'update-policy': '', 'source': 'Crossref', 'is-referenced-by-count': 24, 'title': 'COVID-19 morbidity decreases with tixagevimab–cilgavimab preexposure prophylaxis in kidney ' 'transplant recipient nonresponders or low-vaccine responders', 'prefix': '10.1016', 'volume': '102', 'author': [ {'given': 'Hannah', 'family': 'Kaminski', 'sequence': 'first', 'affiliation': []}, {'given': 'Mickael', 'family': 'Gigan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Agathe', 'family': 'Vermorel', 'sequence': 'additional', 'affiliation': []}, {'given': 'Manon', 'family': 'Charrier', 'sequence': 'additional', 'affiliation': []}, {'given': 'Laura', 'family': 'Guirle', 'sequence': 'additional', 'affiliation': []}, {'given': 'Frederic', 'family': 'Jambon', 'sequence': 'additional', 'affiliation': []}, {'given': 'Arthur', 'family': 'Lacapère', 'sequence': 'additional', 'affiliation': []}, {'given': 'Coline', 'family': 'Ménard', 'sequence': 'additional', 'affiliation': []}, {'given': 'Karine', 'family': 'Moreau', 'sequence': 'additional', 'affiliation': []}, {'given': 'Martine', 'family': 'Neau-Cransac', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marine', 'family': 'Novion', 'sequence': 'additional', 'affiliation': []}, {'given': 'Frederique', 'family': 'Pribat', 'sequence': 'additional', 'affiliation': []}, {'given': 'Benjamin', 'family': 'Taton', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sébastien', 'family': 'Borde', 'sequence': 'additional', 'affiliation': []}, {'given': 'Laure', 'family': 'Burguet', 'sequence': 'additional', 'affiliation': []}, {'given': 'Charlie', 'family': 'Martinez', 'sequence': 'additional', 'affiliation': []}, {'given': 'Magali', 'family': 'Jasiek', 'sequence': 'additional', 'affiliation': []}, {'given': 'Pauline', 'family': 'D’Halluin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marie-Edith', 'family': 'Lafon', 'sequence': 'additional', 'affiliation': []}, {'given': 'Pierre', 'family': 'Merville', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lionel', 'family': 'Couzi', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.kint.2022.07.008_bib1', 'doi-asserted-by': 'crossref', 'first-page': '1549', 'DOI': '10.1016/j.kint.2020.08.005', 'article-title': 'An initial report from the French SOT COVID Registry suggests high ' 'mortality due to Covid-19 in recipients of kidney transplants', 'volume': '98', 'author': 'Caillard', 'year': '2020', 'journal-title': 'Kidney Int'}, { 'key': '10.1016/j.kint.2022.07.008_bib2', 'doi-asserted-by': 'crossref', 'first-page': '2147', 'DOI': '10.1681/ASN.2021040480', 'article-title': 'Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 ' 'vaccine in kidney transplant recipients and hemodialysis patients', 'volume': '32', 'author': 'Bertrand', 'year': '2021', 'journal-title': 'J\xa0Am Soc Nephrol'}, { 'key': '10.1016/j.kint.2022.07.008_bib3', 'doi-asserted-by': 'crossref', 'first-page': '2188', 'DOI': '10.1056/NEJMoa2116620', 'article-title': 'Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of ' 'Covid-19', 'volume': '386', 'author': 'Levin', 'year': '2022', 'journal-title': 'N\xa0Engl J Med'}, { 'key': '10.1016/j.kint.2022.07.008_bib4', 'doi-asserted-by': 'crossref', 'first-page': '553', 'DOI': '10.1038/s41586-022-04594-4', 'article-title': 'Antibody evasion properties of SARS-CoV-2 Omicron sublineages', 'volume': '604', 'author': 'Iketani', 'year': '2022', 'journal-title': 'Nature'}, { 'key': '10.1016/j.kint.2022.07.008_bib5', 'doi-asserted-by': 'crossref', 'first-page': '1475', 'DOI': '10.1056/NEJMc2201933', 'article-title': 'Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant ' 'BA.2', 'volume': '386', 'author': 'Takashita', 'year': '2022', 'journal-title': 'N\xa0Engl J Med'}, { 'key': '10.1016/j.kint.2022.07.008_bib6', 'doi-asserted-by': 'crossref', 'first-page': '440', 'DOI': '10.1016/j.kint.2022.05.007', 'article-title': 'Efficacy of anti-SARS-CoV-2 monoclonal antibody prophylaxis and ' 'vaccination on the Omicron variant of COVID-19 in kidney transplant ' 'recipients', 'volume': '102', 'author': 'Bertrand', 'year': '2022', 'journal-title': 'Kidney Int'}, { 'key': '10.1016/j.kint.2022.07.008_bib7', 'doi-asserted-by': 'crossref', 'first-page': '442', 'DOI': '10.1016/j.kint.2022.05.008', 'article-title': 'Pre-exposure prophylaxis with 300 mg Evusheld elicits limited ' 'neutralizing activity against the Omicron variant', 'volume': '102', 'author': 'Benotmane', 'year': '2022', 'journal-title': 'Kidney Int'}], 'container-title': 'Kidney International', 'original-title': [], 'language': 'en', 'link': [ { 'URL': '', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': '', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 9, 20]], 'date-time': '2022-09-20T09:32:22Z', 'timestamp': 1663666342000}, 'score': 1, 'resource': {'primary': {'URL': ''}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 10]]}, 'references-count': 7, 'journal-issue': {'issue': '4', 'published-print': {'date-parts': [[2022, 10]]}}, 'alternative-id': ['S0085253822005506'], 'URL': '', 'relation': {}, 'ISSN': ['0085-2538'], 'subject': ['Nephrology'], 'container-title-short': 'Kidney International', 'published': {'date-parts': [[2022, 10]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'COVID-19 morbidity decreases with tixagevimab–cilgavimab preexposure ' 'prophylaxis in kidney transplant recipient nonresponders or low-vaccine ' 'responders', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Kidney International', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': '', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'simple-article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2022 International Society of Nephrology. Published by Elsevier Inc. All ' 'rights reserved.', 'name': 'copyright', 'label': 'Copyright'}]}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop